Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
AssigneePfizer Inc.
InventorsWilliam Stephen Faraci, Willard McKowan Welch, Jr.
Life of this patent
Estimating the term…
Loading patent…
AssigneePfizer Inc.
InventorsWilliam Stephen Faraci, Willard McKowan Welch, Jr.
Estimating the term…
The pyrazoles and pyrazolopyrimidines of the formula wherein R1, R2, R3, R4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.
A composition for the treatment of (a) illnesses induced or facilitated by corticotropin releasing factor or (b) stress-induced illnesses, which comprises a compound of the formula
Dependencies are inferred from the claim text.
From the US filing history. Foreign family members aren’t listed.
Drawings are temporarily unavailable. Open the PDF at USPTO
With oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6: two oxygen atoms
With hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals,…:…
With hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals,…:…
With hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals,…:…
Term ended 17 Dec 2012 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
This invention relates to pyrazoles and pyrazolopyrimidines, pharmaceutical compositions containing them, and methods of administering them to subjects in need of their corticotropin-releasing factor (CRF) antagonist activity.
CRF antagonists are mentioned in U.S. Pat. Nos. 4,605,642 and 5,063,245 referring to peptides and pyrazolinones, respectively. The importance of CRF antagonists is set out in the literature, e.g. as discussed in U.S. Pat. No. 5,063,245, which is incorporated herein by reference. A recent outline of the different activities possessed by CRF antagonists is found in M. J. Owens et al., Pharm. Rev., Vol. 43, pages 425 to 473 (1991), also incorporated herein by reference. Based on the research described in these two and other references, CRF antagonists are effective in the treatment of a wide range of diseases including stress-related illnesses, such as stress-induced depression, anxiety, and headache; abdominal bowel syndrome; inflammatory diseases; immune suppression; human immunodeficiency virus (HIV) infections; Alzheimer's disease; gastrointestinal diseases; anorexia nervosa; hemorrhagic stress; drug and alcohol withdrawal symptoms; drug addiction, and fertility problems.
The compound of formula I below wherein A is C═O, R1 is amino, R2 is methylthio, R3 is 2-chlorophenyl, and R4 is 2,4,6-trichlorophenyl is a commercial compound of no known utility.
A. 2-Bromo-2′,5′-dimethylacetophenone
A mixture of 10.60 g (0.10 mol) of para-xylene and 16.53 g (0.105 mol) of α-bromoacetyl chloride in 300 mL of 1,2-dichloroethane was cooled in an ice bath under an atmosphere of dry N2 and treated portionwise with 14.15 g (0.106 mol) of aluminum chloride. The reaction mixture was stirred for 30 minutes at 0-5° C. and then for 2.5 hours at room temperature. The mixture was then poured onto ice and the aqueous layer was acidified with concentrated HCl. The organic layer was separated and the aqueous layer was extracted twice with methylene dichloride. The combined organic extracts were dried with brine solution and with magnesium sulfate. The solvent was evaporated to give 23.87 g of an amber oil which was for use in the next reaction without further purification.
B. 2-Cyano-2′,5′-dimethylacetophenone